Urolift for Enlarged Prostate

This trial tests whether the Urolift treatment can reduce urinary problems caused by prostate cancer radiation therapy. Urolift, a minimally invasive procedure, may help ease symptoms such as frequent urination and discomfort. The trial targets men with prostate cancer requiring radiation and an enlarged prostate (BPH). Ideal participants have been diagnosed with both prostate cancer and BPH but do not have certain urinary conditions or infections. Participants will undergo the Urolift procedure before starting radiation therapy. As an unphased trial, this study provides an opportunity to explore new ways to improve quality of life during cancer treatment.

Research has shown that the UroLift system is generally safe and effective for treating prostate problems. One study found that 92.2% of men experienced successful results over two years, with improved urine flow and reduced symptoms. Most side effects are mild and short-lived, including blood in the urine, discomfort during urination, and pelvic pain, which typically resolve quickly. The complication rate in hospitals was low, at just 3.4%. This evidence suggests that UroLift is a reliable and safe option for managing prostate conditions.¹²³⁴⁵

Unlike the standard treatments for prostate cancer and BPH, which often involve surgery, radiation, or medication, Urolift offers a less invasive option. Urolift is unique because it is a one-time, minimally invasive procedure that lifts and holds the enlarged prostate tissue out of the way, relieving urinary obstruction without cutting, heating, or removing tissue. Researchers are excited about Urolift because it has the potential to reduce urinary side effects typically associated with radiation therapy like SBRT, improving the quality of life for patients undergoing prostate cancer treatment.

Research has shown that the Urolift system effectively treats benign prostatic hyperplasia (BPH), an enlargement of the prostate. Studies have found that patients receiving Urolift implants often experience quick relief and improved urine flow. Most men report feeling "much" or "very much better" just one month after the procedure. Long-term results indicate a low need for additional surgery, with only about 13.6% of patients requiring retreatment over five years. In this trial, participants will receive a one-time administration of Urolift before SBRT (stereotactic body radiation therapy) for prostate cancer treatment, which may help reduce urinary symptoms even after prostate cancer treatments.⁶⁷⁸⁹¹⁰